Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 27;64(2):e02165-19.
doi: 10.1128/AAC.02165-19. Print 2020 Jan 27.

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Pablo A Fraile-Ribot  1 , Laura Zamorano  2 , Rocío Orellana  1 , Ester Del Barrio-Tofiño  1 , Irina Sánchez-Diener  1 , Sara Cortes-Lara  1 , Carla López-Causapé  1 , Gabriel Cabot  1 , Germán Bou  3 , Luis Martínez-Martínez  4 , Antonio Oliver  2 ; GEMARA-SEIMC/REIPI Pseudomonas Study Group
Collaborators, Affiliations

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Pablo A Fraile-Ribot et al. Antimicrob Agents Chemother. .

Abstract

Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.

Keywords: Pseudomonas aeruginosa; antibiotic resistance; extensively drug resistant; imipenem-relebactam; multidrug resistance; whole-genome sequencing; β-lactam resistance mechanisms.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Distribution of imipenem (IMI) and imipenem-relebactam (IMI/REL) MICs for complete collection of clinical isolates and those showing an XDR phenotype.
See this image and copyright information in PMC

References

    1. Juan C, Peña C, Oliver A. 2017. Host and pathogen biomarkers for severe Pseudomonas aeruginosa infections. J Infect Dis 215(Suppl 1):S44–S51. doi:10.1093/infdis/jiw299. - DOI - PubMed
    1. Potron A, Poirel L, Nordmann P. 2015. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568–585. doi:10.1016/j.ijantimicag.2015.03.001. - DOI - PubMed
    1. Oliver A, Mulet X, López-Causapé C, Juan C. 2015. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 21-22:41–59. doi:10.1016/j.drup.2015.08.002. - DOI - PubMed
    1. Van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 63:234–241. doi:10.1093/cid/ciw243. - DOI - PMC - PubMed
    1. Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 54:1213–1217. doi:10.1128/AAC.01104-09. - DOI - PMC - PubMed

Publication types

MeSH terms